- Avantor, Inc. has already reported its first-quarter 2026 results, with sales holding at US$1,581.4 million, while net income fell to US$43.3 million and basic and diluted earnings per share from continuing operations both declined to US$0.06 compared with the prior year.
- The combination of flat revenue and weaker profitability highlights pressure on Avantor’s margins, raising questions about the effectiveness and timing of its ongoing cost and efficiency initiatives.
- We’ll now examine how Avantor’s flat sales but reduced earnings in the latest quarter may influence its longer-term investment narrative.
Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
Avantor Investment Narrative Recap
To be comfortable owning Avantor today, you need to believe its broad role in mission-critical lab and bioprocessing supplies can ultimately translate into healthier margins, not just stable sales. The latest quarter’s flat revenue at US$1,581.4 million but weaker earnings underscores that the most important near term catalyst is credible margin improvement, while the biggest risk remains sustained pressure from aggressive pricing and cost inflation. So far, this earnings print does not fundamentally change that risk balance.
Among recent developments, the appointment of Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer in late April 2026 feels particularly relevant. His remit over both growth and the Revival Management Office ties directly into the cost and efficiency narrative now in focus, especially after another quarter of margin compression. For investors watching Avantor, execution under this refreshed leadership team will likely frame how they judge the company’s response to the latest results.
Yet despite flat Q1 sales, the real information investors should be aware of is how ongoing price pressure and rebates could keep margins under strain...
Read the full narrative on Avantor (it's free!)
Avantor's narrative projects $6.9 billion revenue and $603.4 million earnings by 2029. This requires 1.8% yearly revenue growth and about a $1.15 billion earnings increase from -$551.4 million today.
Uncover how Avantor's forecasts yield a $9.92 fair value, a 19% upside to its current price.
Exploring Other Perspectives
Before this Q1 miss on earnings, the most pessimistic analysts were already assuming only about 1.4% annual revenue growth to roughly US$6.9 billion and shrinking margins, so you should recognize how sharply views can diverge and consider how those assumptions and concerns about rising supply chain and pricing costs might shift after these latest results.
Explore 2 other fair value estimates on Avantor - why the stock might be worth just $9.92!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Avantor research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Avantor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Avantor's overall financial health at a glance.
Contemplating Other Strategies?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com